GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • SAN FRANCISCO— Jody Kearns doesn't like to spend time obsessing about her Parkinson's disease. The 56- year-old dietitian from Syracuse, New York, had to give up bicycling because the disorder affected her balance. More than 75,000 people have enrolled in health studies that use specialized iPhone apps, built with software Apple Inc. developed to help turn the...

  • UPDATE 1-Bellerophon's heart device fails study Monday, 27 Jul 2015 | 7:31 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was licensed to Bellerophon by BioLineRx Ltd in 2009.. BioLineRx's U.S.-listed shares fell 18 percent to $1.76 in premarket...

  • Bellerophon's heart device fails study Monday, 27 Jul 2015 | 6:36 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was tested in 303 patients who had already suffered a heart attack. The device was licensed to Bellerophon by BioLineRx Ltd in...

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • WASHINGTON, July 24- The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended...

  • WASHINGTON— The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. The drug from Sanofi and Regeneron Pharmaceuticals Inc. offers an important new option for millions of patients at high risk of heart disease. But the drug's sky-high...

  • He lost half of a year's normal production and income and won't be able to sell turkeys for months, but the central Minnesota farmer feels good to be getting back to normal. A USDA update Friday said scientists still haven't nailed down the specific ways the virus spreads from the wild into barns but research is continuing in Iowa, Nebraska, Minnesota, the Dakotas...

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • July 24- The U.S. Food and Drug Administration approved AbbVie Inc's treatment that targets hepatitis C virus with the rarest genotype, or genetic makeup. The three drugs included in Technivie are also in Viekira Pak, AbbVie's treatment for genotype 1 hep C virus infection. Separately, AbbVie reported lower-than-expected revenue for the first time in six...

  • Abbvie gets U.S. FDA approval for Hep C drug Friday, 24 Jul 2015 | 11:42 AM ET

    July 24- The U.S. Food and Drug Administration approved Abbvie Inc's treatment that targets the most common genotype, or genetic makeup, of hepatitis C virus. The drug, Technivie, was approved for the treatment of hepatitis C virus genotype 4 infections, the regulator said on Friday. The drug is approved for use in combination with the compound, ribavirin, for the...

  • How effective is new malaria vaccine? Friday, 24 Jul 2015 | 11:40 AM ET
    How effective is new malaria vaccine?

    Suki Virji, analyst for Scrip Intelligence, discusses the malaria vaccine developed by GlaxoSmithKline, which has received a "green light" by the European Medicines Agency.

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...

  • *Sanofi/ Regeneron PCSK9 drug Praluent endorsed by EMA. *Praluent to compete with Amgen's rival product Repatha. LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

  • July 24- Sales of Biogen Inc's roster of multiple sclerosis drugs failed to meet analysts' expectation, prompting the company to slash its full-year profit and sales forecast. Tecfidera's sales were $833 million in the second quarter ended June 30, well below Wall Street's estimate of about $933 million, according to Evercore ISI. Sales of Biogen's injectable...

  • LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen. Amgen's Repatha was formally approved by the European Commission on Tuesday after a positive EMA opinion in May and Praluent is likely to be cleared by the Commission after a...

  • *EU regulators back GSK's Mosquirix for babies in Africa. LONDON, July 24- The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it as safe and effective to use in babies in Africa at risk of the mosquito-borne disease. Mosquirix, also known as RTS, S and part-funded by the Bill& Melinda Gates Foundation, will now...

  • Blood testing goes digital: CEO Friday, 24 Jul 2015 | 4:30 AM ET
    Blood testing goes digital: CEO

    Yossi Pollak, chief executive officer at Sight Diagnostics, explains how computer algorithms make blood testing more efficient.

  • LONDON, July 24- The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease. Recommendations for a drug licence made by the European Medicines Agency are normally endorsed by the European Commission within a couple of...